Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants

Next Previous
Trial Profile

A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin/ezetimibe (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 28 Sep 2022 Primary endpoint (Percent Change from Baseline in LDL-C at Week 12 (Cohort B)) has been met, according to Results published in the Clinical Therapeutics.
  • 28 Sep 2022 Primary endpoint (Percent Change from Baseline in LDL-C at Week 12 (Cohort A)) has been met, according to Results published in the Clinical Therapeutics.
  • 28 Sep 2022 Results comparing efficacy and tolerability of a fixed-dose combination (FDC) of ezetimibe/atorvastatin (EZ/AS) with those of escalating doses of atorvastatin monotherapy in Chinese patients with hypercholesterolemia uncontrolled with statin monotherapy, published in the Clinical Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top